Pipeline

MAKING“EXTRA-ORDINARY” POSSIBLESTARTSHERE

A pipeline for complement-mediated and rare diseases

We are committed to discovering and developing rare disease therapeutics that not only have the potential to move the needle, but improve the lives of people living with complement-mediated and rare diseases—restoring a sense of freedom for them and their loved ones.

Asset
Program
Approved / Commercial
Early / Mid Stage
Late Stage (PH2 - PH 3)
Lead Optimization
Pre-clinical
Phase
ORLADEYO® (berotralstat) Oral Plasma
Kallikrein Inhibitor
Hereditary Angioedema (HAE)
Approved / Commercial

ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

RAPIVAB®(peramivir
injection)
Infectious diseases
Approved / Commercial

RAPIVAB is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than two days.

BCX10013 – Oral Factor D Inhibitor
Complement-mediated diseases
Early / Mid Stage

BCX10013 is a potential once-daily, oral Factor-D inhibitor for the treatment of complement-mediated diseases.

Oral Drugs for Complement(Targets Undisclosed)
Complement-mediated diseases
Lead Optimization

BioCryst’s discovery team is designing oral drug candidates for additional targets in the classical, lectin and terminal pathways of the complement system.

*BCX10013 is investigational and has not been deemed safe and effective by the FDA.

This page may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied on this webpage. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst’s documents filed with the SEC and located at https://ir.biocryst.com/financial-information/sec-filings.

Medicines that meet the needs of patients

For someone living with a complement-mediated or rare disease, the concept of being able to go about life without a constant reminder of their condition would represent a world of difference. Restoring a new sense of freedom for patients and their loved ones is our goal. This is why we develop therapies that blend cutting-edge technology and complex science with the convenience of less intense or invasive methods of delivery. Learn more >>